Kyverna
PublicKyverna is now publicly traded
The data on this page reflects Kyverna's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Aug 3, 2023
Total Funding Raised
$60M
Company Overview
Kyverna operates in Healthcare and is based in Emeryville, California. It has raised $60M.
Kyverna (NAS: KYTX) is a biopharmaceutical company specializing in the development of innovative cell therapies for patients with autoimmune diseases.
Sector
Healthcare
AI Layer
Non-AI
Kyverna Comparables
Compare Kyverna with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dualyx | 64% | |
| Hinge Bio | 54% | |
| COUR Pharmaceuticals | 53% |
For institutional investors. Book with your work email.
Kyverna Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Kyverna Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series B |
| jVen Capital | Series B |
| CAM Capital | Series B |
| Westlake Village BioPartners | Series B |
| GordonMD Global Investments | Series B |
| LYFE Capital | Series B |
| Vida Ventures | Series B |
For institutional investors. Book with your work email.
Kyverna Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.